A Phase 1 Single Ascending Dose study of JN-0413
Latest Information Update: 14 Oct 2025
At a glance
- Drugs JN 0413 (Primary)
- Indications Cognition disorders
- Focus Adverse reactions
- Sponsors Jocasta Neuroscience
Most Recent Events
- 14 Oct 2025 New trial record